Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 223

Sort by

Sort Order Select

Journal Articles

A Dual-Specific Inhibitor of Rock/Aurk, RR-1752, for Primary Myelofibrosis

Liqiang Zhang, Kathryn McGinnis, Paul Gonzales, Maggie Murray, Emily Cluff, MD Babu Mia, Christoph Schaniel, Joseph Mascarenhas, Alan M Miller, Ronald Hoffman, Stephen Gately

Blood (2023) 142 (Supplement 1): 4529.

https://doi.org/10.1182/blood-2023-182046

Published: 2023

Journal Articles

Do Hematologic Parameters Predict Thrombosis or Disease Transformation in Essential Thrombocythemia?

Hannah Goulart, Dahniel L Sastow, Nicholas Dreher, Metodi Balev, Grace Van Hyfte, Marina Kremyanskaya, Ronald Hoffman, John Mascarenhas, Douglas Tremblay

Blood (2023) 142 (Supplement 1): 3200.

https://doi.org/10.1182/blood-2023-182450

Published: 2023

Journal Articles

Upregulation of Platelet Transcripts As Biomarkers of Fibrotic Progression in Myeloproliferative Neoplasms

Anitria Cotton, Ryan Collinson, Lynne Wilson, Zi Yun Ng, Hun S Chuah, Michael F. Leahy, Rebecca Howman, Carolyn Grove, Hasib Sidiqi, Malcolm Webb, Darren Boey, Olivia Ruhen, Michael Phillips, Matthew Linden, Kathy Fuller, Wendy N. Erber, Ronald Hoffman, John D. Crispino, Belinda Guo

Blood (2023) 142 (Supplement 1): 4520.

https://doi.org/10.1182/blood-2023-182140

Published: 2023

Journal Articles

Conventional Cytogenetic Analysis and Array CGH+SNP Identify Essential Thrombocythemia (ET)/Prefibrotic Primary Myelofibrosis (pre-PMF) Patients Who Are at Risk for Disease Progression

Joseph Tripodi, Ronald Hoffman, Douglas Tremblay, John Mascarenhas, Marina Kremyanskaya, Ian Novoselac, Vesna Najfeld

Blood (2023) 142 (Supplement 1): 1832.

https://doi.org/10.1182/blood-2023-181092

Published: 2023

Journal Articles

Interpretable Artificial Intelligence (AI) Differentiates Prefibrotic Primary Myelofibrosis (prePMF) from Essential Thrombocythemia (ET): A Multi-Center Study of a New Clinical Decision Support Tool

Andrew Srisuwananukorn, Giuseppe Gaetano Loscocco, Andrew T. Kuykendall, James M Dolezal, Raffaella Santi, Ling Zhang, Avani M Singh, Paola Guglielmelli, Alessandro Maria Vannucchi, Douglas Tremblay, Alexander T Pearson, Mohamed E. Salama, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 901.

https://doi.org/10.1182/blood-2023-173877

Published: 2023

Journal Articles

Durable Clinical Benefits of Idasanutlin Therapy in Hydroxyurea-Refractory Polycythemia Vera

Julian Waksal, Ronald Hoffman, Abdulraheem Yacoub, Francesco Passamonti, Aaron T. Gerds, Vikas Gupta, Grace Van Hyfte, Jayanshu Jain, Margherita Maffioli, Natalia Rosas, John Mascarenhas

Blood (2023) 142 (Supplement 1): 3187.

https://doi.org/10.1182/blood-2023-182116

Published: 2023

Journal Articles

The Presence of Ring Chromosomes in Patients with Myeloid Neoplasms Is Predictive of a Poor Outcome

Daniel I. Nathan, Ronald Hoffman, Daiva Ahire, John Mascarenhas, Lewis R. Silverman, Vesna Najfeld, Jonathan Feld

Blood (2023) 142 (Supplement 1): 2940.

https://doi.org/10.1182/blood-2023-179585

Published: 2023

Journal Articles

TL-895, a Highly Selective, Covalent Inhibitor of Bruton's Tyrosine Kinase (BTK), Sensitizes Myeloproliferative Neoplasm (MPN)-Blast Phase Stem Cells to Navtemadlin By Targeting Intrinsic Dysregulated MDM2/p53 and NF-Κb Pathways and Disrupting the Protective Tumor Microenvironment (TME)

Xiaoli Wang, Andrew Davis, Xiaoping Su, Muharrem Muftuoglu, Cecile Krejsa, John Mascarenhas, Michael Andreeff, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 4523.

https://doi.org/10.1182/blood-2023-187426

Published: 2023

Journal Articles

Thrombocytopenia Associated with Myelofibrosis Is Characterized By a Reduced Proportion of Megakaryocyte (MK) Biased Hematopoietic Stem Cells, Defects in MK Maturation and Increased Levels of Pro-Inflammatory Cytokines

Lilian Varricchio, Gohar Mosoyan, Sebastian Elghaity-beckley, John Mascarenhas, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 1779.

https://doi.org/10.1182/blood-2023-178087

Published: 2023

Journal Articles

Use of Combination Therapies Including the XPO1 Inhibitor Selinexor in Is a Potential Effective Therapeutic Strategy to Treat Myelofibrosis Patients

Min Lu, Lijuan Xia, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 1792.

https://doi.org/10.1182/blood-2023-186674

Published: 2023

Journal Articles

Oral Decitabine/Cedazuridine Is a Tolerable and Effective Ambulatory Regimen for Patients with Advanced Myeloproliferative Neoplasms

Ganesh Sivakumar, Shivani Handa, Andrew Srisuwananukorn, Douglas Tremblay, John Mascarenhas, Marina Kremyanskaya, Yelena Ginzburg, Xiaoli Wang, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 1828.

https://doi.org/10.1182/blood-2023-178822

Published: 2023

Journal Articles

CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis

Blood (2023) 141 (20): 2508–2519.

https://doi.org/10.1182/blood.2022015418

Published: 2023

Includes: Supplemental data

Journal Articles

IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms

Johanna Melo-Cardenas, Lavanya Bezavada, Jeremy Chase Crawford, Sandeep Gurbuxani, Anitria Cotton, Guolian Kang, Jeffrey Gossett, Christian Marinaccio, Rona Weinberg, Ronald Hoffman, Anna Rita Migliaccio, Yan Zheng, Marta Derecka, Ciro R. Rinaldi, John D. Crispino

Blood (2022) 140 (26): 2805–2817.

https://doi.org/10.1182/blood.2022017326

Published: 2022

Includes: Supplemental data

Journal Articles

Subgroup Analysis of Adverse Events Following Rusfertide Dosing in Revive: A Phase 2 Study of Patients with Polycythemia Vera

Naveen Pemmaraju, Srdan Verstovsek, Marina Kremyanskaya, Frank Valone, Nishit B. Modi, Sarita Khanna, Paula G. O'Connor, Suneel K. Gupta, Ronald Hoffman

Blood (2022) 140 (Supplement 1): 6835–6837.

https://doi.org/10.1182/blood-2022-163742

Published: 2022

Journal Articles

Transcriptional and Epigenetic Dysregulation Drives Erythroid and Megakaryocyte Differentiation Bias in the Spleens of Patients with Advanced Myelofibrosis

Rebecca Austin, Madeline Kowalski, Xiaoli Wang, Bettina Nadorp, Audrey Lasry, Zhengxi Sun, Julia Rojo-Tomillo, Andrew Davis, Dimitrios Papaioannou, Rahul Satija, Ioannis Aifantis, Ronald Hoffman

Blood (2022) 140 (Supplement 1): 9584–9585.

https://doi.org/10.1182/blood-2022-170220

Published: 2022

Journal Articles

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Blood (2022) 140 (Supplement 1): 614–616.

https://doi.org/10.1182/blood-2022-165646

Published: 2022

Journal Articles

Co-Cultivation of MF CD34+ Cells with Microenvironmental Cells Has a Profound Effect on MF Hematopoiesis and Responses to Drug Therapy

Min Lu, Christoph Schaniel, Jeff Vierstra, Lijuan Xia, Ronald Hoffman

Blood (2022) 140 (Supplement 1): 8625–8626.

https://doi.org/10.1182/blood-2022-170704

Published: 2022

Journal Articles

Molecularly Targeted Combination Therapy for Advanced Phase Myeloproliferative Neoplasm: MPN-RC 119

Michal Bar-Natan, John Mascarenhas, Aaron T. Gerds, Ruben Mesa, Vikas Gupta, Marina Kremyanskaya, Mikaela Dougherty, Frank Fabris, Kathryn Johnson, Ashley Yu, Heidi E. Kosiorek, Carolyn Mead-Harvey, Amylou C. Dueck, Ronald Hoffman, Raajit K Rampal

Blood (2022) 140 (Supplement 1): 3988–3990.

https://doi.org/10.1182/blood-2022-164678

Published: 2022

Journal Articles

Rusfertide for Polycythemia Vera: Similar Dosing in Patients Receiving Therapeutic Phlebotomy Alone or in Combination with Cytoreductive Treatment

Aaron T. Gerds, Jason Gotlib, Jeanne M. Palmer, Naveen Pemmaraju, Prithviraj Bose, Yelena Ginzburg, Frank Valone, Nishit B. Modi, Sarita Khanna, Paula G. O'Connor, Suneel K. Gupta, Ronald Hoffman

Blood (2022) 140 (Supplement 1): 12241–12243.

https://doi.org/10.1182/blood-2022-163847

Published: 2022

Journal Articles

ATR Inhibitor Camonsertib (RP-3500) Suppresses Early Stage Erythroblasts By Mediating Ferroptosis

Maayan Levy, Gino Ferraro, Li Li, Yongshuai Han, Lilian Varricchio, Sara Fournier, Xiuli An, Ronald Hoffman, Adrian Fretland, Anne Roulston, Yelena Ginzburg

Blood (2022) 140 (Supplement 1): 8194–8195.

https://doi.org/10.1182/blood-2022-169951

Published: 2022

NARROW

A Dual-Specific Inhibitor of Rock/Aurk, RR-1752, for Primary Myelofibrosis

Do Hematologic Parameters Predict Thrombosis or Disease Transformation in Essential Thrombocythemia?

Upregulation of Platelet Transcripts As Biomarkers of Fibrotic Progression in Myeloproliferative Neoplasms

Conventional Cytogenetic Analysis and Array CGH+SNP Identify Essential Thrombocythemia (ET)/Prefibrotic Primary Myelofibrosis (pre-PMF) Patients Who Are at Risk for Disease Progression

Interpretable Artificial Intelligence (AI) Differentiates Prefibrotic Primary Myelofibrosis (prePMF) from Essential Thrombocythemia (ET): A Multi-Center Study of a New Clinical Decision Support Tool

Durable Clinical Benefits of Idasanutlin Therapy in Hydroxyurea-Refractory Polycythemia Vera

The Presence of Ring Chromosomes in Patients with Myeloid Neoplasms Is Predictive of a Poor Outcome

TL-895, a Highly Selective, Covalent Inhibitor of Bruton's Tyrosine Kinase (BTK), Sensitizes Myeloproliferative Neoplasm (MPN)-Blast Phase Stem Cells to Navtemadlin By Targeting Intrinsic Dysregulated MDM2/p53 and NF-Κb Pathways and Disrupting the Protective Tumor Microenvironment (TME)

Thrombocytopenia Associated with Myelofibrosis Is Characterized By a Reduced Proportion of Megakaryocyte (MK) Biased Hematopoietic Stem Cells, Defects in MK Maturation and Increased Levels of Pro-Inflammatory Cytokines

Use of Combination Therapies Including the XPO1 Inhibitor Selinexor in Is a Potential Effective Therapeutic Strategy to Treat Myelofibrosis Patients

Oral Decitabine/Cedazuridine Is a Tolerable and Effective Ambulatory Regimen for Patients with Advanced Myeloproliferative Neoplasms

CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis

IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms

Subgroup Analysis of Adverse Events Following Rusfertide Dosing in Revive: A Phase 2 Study of Patients with Polycythemia Vera

Transcriptional and Epigenetic Dysregulation Drives Erythroid and Megakaryocyte Differentiation Bias in the Spleens of Patients with Advanced Myelofibrosis

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Co-Cultivation of MF CD34+ Cells with Microenvironmental Cells Has a Profound Effect on MF Hematopoiesis and Responses to Drug Therapy

Molecularly Targeted Combination Therapy for Advanced Phase Myeloproliferative Neoplasm: MPN-RC 119

Rusfertide for Polycythemia Vera: Similar Dosing in Patients Receiving Therapeutic Phlebotomy Alone or in Combination with Cytoreductive Treatment

ATR Inhibitor Camonsertib (RP-3500) Suppresses Early Stage Erythroblasts By Mediating Ferroptosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only